Menu
1 min read · estimated
APPROVED USE
What FDA approved
Restricts first-line maintenance after complete or partial response to platinum chemotherapy in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to homologous recombination deficiency-positive disease, defined by a deleterious or suspected deleterious BRCA mutation or genomic instability.
LAMPGEN ANALYSIS
Why it matters
FDA narrowed the previous first-line maintenance label to an HRD-positive population.
What research teams should watch
Obtain HRD information in time for the maintenance decision and distinguish this first-line restriction from the separate recurrent maintenance label.
PRIMARY RECORDS